CCR5 and AIDS: While genome editing is widely accepted as a promising therapy for hereditary disorders, its potential in treating high‐risk infectious diseases (e.g., AIDS) by disrupting key host factors (e.g., C–C chemokine receptor type 5, CCR5) has only started to be explored recently.33